Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liabilities (current) of $0 in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current) decreased by 100.0% year-over-year, from $384K to $0.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (current) has grown at a -100.0% compound annual growth rate (CAGR), from $282K to $0.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.